Compare TSBK & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TSBK | DCTH |
|---|---|---|
| Founded | 1915 | 1988 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.0M | 363.5M |
| IPO Year | 1997 | 2015 |
| Metric | TSBK | DCTH |
|---|---|---|
| Price | $41.00 | $11.10 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $22.00 |
| AVG Volume (30 Days) | 18.2K | ★ 401.5K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.87% | N/A |
| EPS Growth | 21.93 | ★ 107.53 |
| EPS | ★ 1.94 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $24.54 |
| Revenue Next Year | N/A | $33.15 |
| P/E Ratio | $21.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $29.30 | $8.12 |
| 52 Week High | $43.55 | $17.34 |
| Indicator | TSBK | DCTH |
|---|---|---|
| Relative Strength Index (RSI) | 49.19 | 52.26 |
| Support Level | $39.81 | $10.22 |
| Resistance Level | $42.40 | $11.24 |
| Average True Range (ATR) | 0.99 | 0.58 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 53.16 | 25.32 |
Timberland Bancorp Inc is a bank holding company for Timberland Bank. The bank offers banking services including personal checking and savings accounts, debit cards, health savings accounts, online and mobile banking, online bill pay, 24-hour phone banking, and Zelle. Business services include business checking accounts, online banking, remote deposit, ACH transactions, Autobooks, and insured cash sweep services. The bank also provides lending services such as personal credit cards, home loans, home equity borrowing, construction loans, and SBA loans. In addition, it offers loans to real estate, including residential and commercial real estate, multi-family construction loans, one- to four-family residential loans, multi-family loans, commercial real estate loans, and land loans.
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.